Gyros AB appoints US Director of Sales for Gyros US Inc.
Gyros AB appoints US Director of Sales for Gyros US Inc. Gyros AB announced today the appointment of the Director of Sales for the company's new Gyros US Inc. organization in Princeton, New Jersey. Gyros AB announced today the appointment of John Shomers as Director of Sales for the new Gyros US Inc. to be based in Princeton, New Jersey. "Mr Shomers will begin the build-up of our US organization." said Richard Millett, Vice President Sales. "John has held several senior sales management positions, most recently with Molecular Devices in Sunnyvale, California, and has over 20 years of experience in the biotechnology business area. His depth of experience will be invaluable during this crucial development phase." The Company began development of its sales and marketing organization in December 2000 with the establishment of a subsidiary in the United Kingdom and anticipates a continued rapid expansion in preparation for major product launches in 2002. The Gyros technology platform has the potential to miniaturize and integrate many different laboratory processes and the Company will focus its initial marketing efforts towards the proteomics area in drug discovery. "With the US market in proteomics continuing to expand rapidly, we believe that our internal knowledge and expertise is well suited to accelerate the development of enabling products for this market." said Per Sjöberg, Executive Vice President Commercial Operations "The high concentration of biotech and pharmaceutical companies working around the Princeton area will facilitate close contact with many of our future clients. Excellent communication with our clients will be a key element for the development of our customized solutions as well as for the introduction of our first products." Sjöberg continued: "Major pharmaceutical companies in Europe and the US have already expressed strong interest in our unique new technology platform. This interest more than justifies the build up of our US and European organizations to support future sales and marketing efforts." The US Director of Sales, John Shomers, can be contacted at Gyros US Inc., Princeton Overlook One, 100 Overlook Center, Princeton, NJ 08540, Tel +1-609-448-8895, Toll free (in USA) 866-448-8895. About Gyros AB Gyros AB offers pharmaceutical, biotechnology and diagnostic companies access to a unique, proprietary technology platform in which routine or non-routine laboratory processes can be miniaturized and integrated into client-specific CDs. Hundreds of samples can be processed in parallel on these disposable microlaboratories. This new platform brings outstanding gains in efficiency, cost-effectiveness and information content. The ability to integrate different laboratory steps on a single CD offers the potential to reassess and redesign traditional working procedures. The company was founded in 2000 and has its offices based in the Science Park in Uppsala, Sweden. For further information, visit www.gyrosmicro.com or contact: Maris Hartmanis, President and CEO, Gyros AB Tel: +46 (0)18 566 330 Mobile: +46 (0)70 562 8617 Email: email@example.com Per Sjöberg, Executive Vice President Commercial Operations, Gyros AB Tel: +46 (0)18 566 318 Mobile: +46 (0)70 5444799 Email: firstname.lastname@example.org Media information (trade): Sue Cresswell, Marketing Communications Tel: +46 (0)8 54472620 Mobile: +46 (0)705 519520 Email: email@example.com Statements in this press release that are not strictly historical may be forward-looking and include risks and uncertainties. Therefore, though based on Gyros' current expectations, it should be duly noted that a variety of factors could cause actual results and experiences to differ materially from what is herein expressed. Risks and uncertainties include, but are not limited to, risks associated with the management of growth and international operations (including effects of currency fluctuations), variability of operating results, unforeseen changes in the diagnostic and pharmaceutical markets, market competition, rapid or unexpected changes in technologies, fluctuations in product demand, difficulties to successfully develop, adapt, produce or commercialize products, the ability to identify and develop new products and to differentiate products from those of competitors, as well as various legal hazards. ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.bit.se/bitonline/2001/06/25/20010621BIT00620/bit0001.doc http://www.bit.se/bitonline/2001/06/25/20010621BIT00620/bit0001.pdf